Author

Jun J. Yang

St. Jude Children's Research HospitalPrimary ORCID profile (0000-0002-4965-2929 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Jun J. YangiD1 paper · University of California, Davis

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Anagha Inguva· 1 shared Angelo D’AlessandroiD· 1 shared Ben Kooiman· 1 shared Brett Stevens· 1 shared Craig T. JordaniD· 1 shared Dallas Jones· 1 shared Daniel StephensoniD· 1 shared Dejene Tufa· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anagha Inguva

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using Venetoclax

Dallas Jones, Elena Woods, Zhenhua Li, Kristin L. Schaller, Eric Hoffmeyer, Ben Kooiman, Joseph Fernandez, Tegan Wharton, Dejene Tufa, Spencer C. Hall, George Trahan, Kelly W. Maloney, Holly Pacenta, Kelly Sullivan, Joaquin Espinosa, , Michael R. Verneris

This study identifies metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia and shows that Venetoclax effectively targets these vulnerabilities.

Haematologica · Oct 22, 2026Peer-reviewedCancer Biology